Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

The week’s most popular albums as compiled by Luminate, based on multi-metric consumption (blending traditional album sales, track equivalent albums, and streaming equivalent albums). click to see ...